MetaCap

Neuphoria Therapeutics Inc. (NEUP)

NASDAQ: NEUPHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.35+0.03 (+1.29%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NEUP stock chart

Technical analysis

Key statistics

All statistics
Market cap
$12.72M
EPS (TTM)
-$2.07
52-week range
2.26 – 5.53
Day range
2.27 – 2.38
Volume / Avg
55.96K / 26.53K
Beta
—

52-week range

$2.26$5.53

NEUP stock today

Neuphoria Therapeutics (NEUP) closed at $2.35 on Nov 20, up 1.29% (+$0.03), versus the S&P 500's 3.70% decline. Volume was 2.1x the average at 55.96K shares, a sign of unusually heavy trading. At this level, NEUP sits near the bottom of its 52-week range of $2.26 to $5.53: 57.5% below the high, set on May 22, 2026 and 4.0% above the low.

NEUP is down 39.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 47.3%. Neuphoria Therapeutics has posted a net loss over the last twelve months (EPS of -$2.07), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Neuphoria Therapeutics

Company profile

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Spyridon Papapetropoulos M.D., Ph.D.
Headquarters
Millis, MA
Employees
1
IPO year
2021

Financial highlights

Full financials

In fiscal 2026, Neuphoria Therapeutics generated $1.2 million in revenue, down 92.5% from fiscal 2025, the first decline in the 4 years shown. Neuphoria Therapeutics reported a net loss of $13.5 million, compared with a loss of $369,632 a year earlier. Operating margin was -1401.1%.

Neuphoria Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024FY 2023
Revenue$1.17M$15.65M——
Growth-92.50%———
Net income$-13.45M$-369.63K$-15.49M$-21.38M
EPS (diluted)$-3.06$-0.23$-18.62$-0.02

Analyst forecast

Forecast

Consensus (1 analysts)

none

  • Strong buy 0
  • Buy 0
  • Hold 1
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-0.26 vs —

NEUP news

All NEUP news

Neuphoria Therapeutics peers

Health Care sector
NEUP peer companies
CompanyPrice% ChgMarket capCompare
ALLRAllarity Therapeutics Inc.0.785-9.25%$12.56Mvs NEUP
MCRBSeres Therapeutics Inc.1.24-6.77%$12.64Mvs NEUP
MIRAMIRA Pharmaceuticals Inc.0.291-20.84%$12.23Mvs NEUP
BOLTBolt Biotherapeutics Inc.4.91-2.96%$12.80Mvs NEUP
TVRDTvardi Therapeutics Inc.0.9893+4.57%$13.22Mvs NEUP
ACTUActuate Therapeutics Inc.0.2253+5.38%$13.60Mvs NEUP
BYSIBeyondSpring Inc.0.33-24.49%$13.66Mvs NEUP
CTXRCitius Pharmaceuticals Inc.0.5085+2.27%$13.96Mvs NEUP

Indexes, lists and sector

Neuphoria Therapeutics stock FAQ

What is Neuphoria Therapeutics's stock price today?

NEUP last traded at $2.35 as of Nov 20, 4:00 PM EST, up 1.29% on the day. Prices are delayed at least 15 minutes.

Does Neuphoria Therapeutics pay a dividend?

No. Neuphoria Therapeutics does not currently pay a regular cash dividend.

Who is Neuphoria Therapeutics's CEO?

Dr. Spyridon Papapetropoulos M.D., Ph.D. is the chief executive officer of Neuphoria Therapeutics Inc., which has about 1 employees.

Has NEUP ever split its stock?

Yes. The most recent NEUP stock split was a 1-for-12 split on Dec 24, 2024.

What is the NEUP 52-week high?

The 52-week high for NEUP is $5.53 and the 52-week low is $2.26. The stock is currently 57.5% below its high.

Compare NEUP